.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Julphar
Boehringer Ingelheim
Johnson and Johnson
Daiichi Sankyo
Dow
AstraZeneca
Novartis
Mallinckrodt
US Army

Generated: September 22, 2017

DrugPatentWatch Database Preview

Venetoclax - Generic Drug Details

« Back to Dashboard

What are the generic sources for venetoclax and what is the scope of venetoclax freedom to operate?

Venetoclax
is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Venetoclax has ninety-two patent family members in thirty-eight countries.

One supplier is listed for this compound.

Summary for Generic Name: venetoclax

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list37
Clinical Trials: see list48
Patent Applications: see list101
Drug Prices:see low prices
DailyMed Link:venetoclax at DailyMed

Pharmacology for Ingredient: venetoclax

Drug ClassBCL-2 Inhibitor
Mechanism of ActionP-Glycoprotein Inhibitors
Physiological EffectIncreased Cellular Death
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-002Apr 11, 2016RXYesNo► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-001Apr 11, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-002Apr 11, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-003Apr 11, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-001Apr 11, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-003Apr 11, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-002Apr 11, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-003Apr 11, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-001Apr 11, 2016RXYesNo► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-001Apr 11, 2016RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: venetoclax

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,580,794Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases► Subscribe
9,045,475Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases► Subscribe
9,034,875Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: venetoclax

Country Document Number Estimated Expiration
New Zealand603463► Subscribe
HungaryE027698► Subscribe
Cyprus1117423► Subscribe
TaiwanI537269► Subscribe
Japan2012528178► Subscribe
Mexico2012013708► Subscribe
China104876927► Subscribe
Ukraine107706► Subscribe
Japan2015110605► Subscribe
Hong Kong1215576► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Express Scripts
Healthtrust
Fish and Richardson
Deloitte
Cantor Fitzgerald
US Army
QuintilesIMS
Merck
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot